Drug Profile


Alternative Names: DCR-M1711; DCR-MYC

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Dicerna Pharmaceuticals
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action Proto oncogene protein c-myc inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatocellular carcinoma; Multiple myeloma; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 07 Oct 2016 Pharmacodynamics data from a phase I DCR-MYC-101 trial in Solid tumours released by Dicerna
  • 26 Sep 2016 Discontinued - Phase-I for Multiple myeloma (Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top